A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (NCT04108195)

🧪 Interventions in This Study

• Daratumumab (DRUG)
• Talquetamab (DRUG)
• Teclistamab (DRUG)
• Pomalidomide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• City of Hope National Medical Center — Duarte, California
• City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
• University of California San Francisco — San Francisco, California
• The Blavatnik Family Chelsea Medical Center at Mount Sinai — New York, New York
• Mount Sinai Medical Center — New York, New York
• Levine Cancer Institute — Charlotte, North Carolina
• Wake Forest Baptist Medical Center — Winston-Salem, North Carolina
• University of Pennsylvania — Philadelphia, Pennsylvania
• Vanderbilt Ingram Cancer Center — Nashville, Tennessee
• Medical College Of Wisconsin — Milwaukee, Wisconsin
• Arthur J E Child Comprehensive Cancer Centre — Calgary, Alberta
• University Health Network UHN Princess Margaret Cancer Centre — Toronto, Ontario
• Universitatsklinikum Freiburg — Freiburg im Breisgau,
• Universitaetsklinikum Hamburg Eppendorf — Hamburg,
• Universitaetsklinikum Heidelberg — Heidelberg,
• Universitatsklinikum Wurzburg — Würzburg,
• VU Medisch Centrum — Amsterdam,
• LUMC — Leiden,
• Hosp Clinic de Barcelona — Barcelona,
• Inst. Cat. Doncologia-H Duran I Reynals — Barcelona,
• Germans Trias I Pujol — Barcelona,
• Hosp Univ Fund Jimenez Diaz — Madrid,
• Clinica Univ. de Navarra — Pamplona,
• Hosp Clinico Univ de Salamanca — Salamanca,

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.